InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement ...

[This article was first published in Army Sustainment Professional Bulletin, which was then called Army Logistician, volume 2, number 5 (September–October 1970), pages 12–13. The text is ...

N.V. announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum and ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

InflaRx will conduct a virtual fireside chat on March 27 at 8:30 AM ET and will participate in one-on-one-investor meetings. A link to register for the fireside chat live stream and its replay is ...

One factor that seems to be involved is C5a, a protein involved in chemotaxis. Theoretically, blocking C5a receptor (C5aR) activity could form a therapeutic strategy for RA. The recently developed ...

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...